CoChat

The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Open access
Rosenblat, Joshua D, Kakar, Ron, McIntyre, Roger S · 2016 · International Journal of Neuropsychopharmacology

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 6 of the 17 sources its claims cite were checked for support.

Abstract

BACKGROUND: Cognitive dysfunction is often present in major depressive disorder (MDD). Several clinical trials have noted a pro-cognitive effect of antidepressants in MDD. The objective of the current systematic review and meta-analysis was to assess the pooled efficacy of antidepressants on various domains of cognition in MDD. METHODS: Trials published prior to April 15, 2015, were identified through searching the Cochrane Central Register of Controlled Trials, PubMed, Embase, PsychINFO, Clinicaltrials.gov, and relevant review articles. Data from randomized clinical trials assessing the cognitive effects of antidepressants were pooled to determine standard mean differences (SMD) using a random-effects model. RESULTS: Nine placebo-controlled randomized trials (2 550 participants) evaluating the cognitive effects of vortioxetine (n = 728), duloxetine (n = 714), paroxetine (n = 23), citalopram (n = 84), phenelzine (n = 28), nortryptiline (n = 32), and sertraline (n = 49) were identified. Antidepressants had a positive effect on psychomotor speed (SMD 0.16; 95% confidence interval [CI] 0.05-0.27; I(2) = 46%) and delayed recall (SMD 0.24; 95% CI 0.15-0.34; I(2) = 0%). The effect on cognitive control and executive function did not reach statistical significance. Of note, after removal of vortioxetine from the analysis, statistical significance was lost for psychomotor speed. Eight head-to-head randomized trials comparing the effects of selective serotonin reuptake inhibitors (SSRIs; n = 371), selective serotonin and norepinephrine reuptake inhibitors (SNRIs; n = 25), tricyclic antidepressants (TCAs; n = 138), and norepinephrine and dopamine reuptake inhibitors (NDRIs; n = 46) were identified. No statistically significant difference in cognitive effects was found when pooling results from head-to-head trials of SSRIs, SNRIs, TCAs, and NDRIs. Significant limitations were the heterogeneity of results, limited number of studies, and small sample sizes. CONCLUSIONS: Available evidence suggests that antidepressants have a significant positive effect on psychomotor speed and delayed recall.

Overview

CoChat Summary

TL;DR

This systematic review and meta-analysis found that antidepressants have small, statistically significant positive effects on psychomotor speed and delayed recall in major depressive disorder, but not on cognitive control or executive function. Head-to-head trials showed no statistically significant differences between antidepressant classes, and the psychomotor speed effect lost significance after removing vortioxetine.

Key findings

  • In nine placebo-controlled randomized trials (2,550 participants), antidepressants improved psychomotor speed (SMD 0.16; 95% CI 0.05–0.27; I² = 46%) and delayed recall (SMD 0.24; 95% CI 0.15–0.34; I² = 0%). Effects on cognitive control (SMD 0.10; 95% CI −0.06 to 0.26; p = 0.21) and executive function (SMD 0.12; 95% CI −0.03 to 0.28; p = 0.12) were not statistically significant.
  • Vortioxetine had the largest pooled effect size (0.34; 95% CI 0.17–0.50; p = 0.0001), followed by duloxetine (0.10; 95% CI −0.01 to 0.22). After removing vortioxetine, the psychomotor speed effect was no longer significant (SMD 0.08; 95% CI −0.02 to 0.18; p = 0.13).
  • In head-to-head trials, no statistically significant difference was found between SSRIs/SNRIs and TCAs on pooled memory domains (SMD 0.33; 95% CI −0.11 to 0.78; p = 0.14), or between SSRIs and NDRIs on working memory (SMD −0.22; 95% CI −0.62 to 0.19). Sertraline outperformed fluoxetine on psychomotor speed (SMD 0.38; 95% CI 0.11–0.66; p = 0.006).
  • A subgroup analysis found a greater positive effect in subjects younger than 65 (SMD 0.23; 95% CI 0.04–0.43; p = 0.02) than in those older than 65 (SMD 0.10; 95% CI 0.00–0.21; p = 0.06), but the difference between subgroups was not statistically significant (p = 0.24).

Methods

  • Systematic review and meta-analysis of randomized clinical trials published before April 15, 2015, identified through Cochrane Central Register of Controlled Trials, PubMed, Embase, PsychINFO, Clinicaltrials.gov, and relevant review articles. Inclusion required adults over 18 with MDD, antidepressant monotherapy with monoamine modulation, and cognition assessed by standardized validated measures.
  • Data were pooled using standard mean differences (SMD) with a random-effects model in Review Manager 5.3. Placebo-controlled trials compared final cognitive scores of antidepressant versus placebo; head-to-head trials compared one antidepressant with another. Risk of bias was assessed across five domains, and a funnel plot was created for psychomotor speed.
  • Searches yielded 1,084 articles plus 23 from reference lists; 45 full texts were reviewed, 25 studies were included qualitatively, and 17 were included quantitatively. Nine placebo-controlled trials and eight head-to-head trials contributed to the meta-analysis.

Limitations

  • The paper states that high heterogeneity of cognitive testing limited comparison and pooling, that moderate heterogeneity was present in pooled SMDs, that the number of studies and sample sizes were small, and that vortioxetine and duloxetine were heavily weighted; removing vortioxetine eliminated statistical significance for psychomotor speed.
  • The paper also states that many included studies had potential for-profit bias due to pharmaceutical company funding, and that the functional meaning of the small cognitive test improvements remains largely unknown.
  • Evident from the text: an Egger test could not be performed because fewer than ten studies were available, funnel plot interpretation was limited, most studies evaluated cognition as a secondary outcome, and responder/non-responder subgroup analyses were not possible due to insufficient reporting.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/ijnp/pyv082

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram of study selection.
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram of study selection.CC BY · PubMed Central
Figure 2. Pooled effect for placebo-controlled trials assessing psychomotor speed. CI, confidence interval; DSST, Digit Symbol Sign Test; SD, standard definition.
Figure 2. Pooled effect for placebo-controlled trials assessing psychomotor speed. CI, confidence interval; DSST, Digit Symbol Sign Test; SD, standard definition.CC BY · PubMed Central
Figure 3. Pooled effect of placebo-controlled trials assessing psychomotor speed sub-grouped based on age greater or less than 65 years. CI, confidence interval; DSST, Digit Symbol Sign Test; SD, standard definition.
Figure 3. Pooled effect of placebo-controlled trials assessing psychomotor speed sub-grouped based on age greater or less than 65 years. CI, confidence interval; DSST, Digit Symbol Sign Test; SD, standard definition.CC BY · PubMed Central
Figure 4. Funnel-plot of placebo-controlled trials assessing psychomotor speed. SE, standard error; SMD, standard mean differences.
Figure 4. Funnel-plot of placebo-controlled trials assessing psychomotor speed. SE, standard error; SMD, standard mean differences.CC BY · PubMed Central
Figure 5. Pooled effect for placebo-controlled trials assessing cognitive control (Stroop test). CI, confidence interval; SD, standard definition.
Figure 5. Pooled effect for placebo-controlled trials assessing cognitive control (Stroop test). CI, confidence interval; SD, standard definition.CC BY · PubMed Central
Figure 6. Pooled effect for placebo-controlled trials assessing executive function (Trails Making Test-B). CI, confidence interval; SD, standard definition.
Figure 6. Pooled effect for placebo-controlled trials assessing executive function (Trails Making Test-B). CI, confidence interval; SD, standard definition.CC BY · PubMed Central
Figure 7. Pooled effect for placebo-controlled trials assessing delayed recall (Rey Auditory Verbal Learning Test). CI, confidence interval; SD, standard definition.
Figure 7. Pooled effect for placebo-controlled trials assessing delayed recall (Rey Auditory Verbal Learning Test). CI, confidence interval; SD, standard definition.CC BY · PubMed Central
Figure 8. Pooled effect on memory for selective serotonin reuptake inhibitors (SSRI)/selective serotonin and norepinephrine reuptake inhibitors (SNRI) versus tricyclic antidepressants (TCA). CI, confidence interval; RBMT, Rivermead Behavioural Memory Test; SD, standard definition; STM, short term memory.
Figure 8. Pooled effect on memory for selective serotonin reuptake inhibitors (SSRI)/selective serotonin and norepinephrine reuptake inhibitors (SNRI) versus tricyclic antidepressants (TCA). CI, confidence interval; RBMT, Rivermead Behavioural Memory Test; SD, standard definition; STM, short term memory.CC BY · PubMed Central
Figure 9. Pooled effect on working memory for selective serotonin reuptake inhibitors (SSRI) versus norepinephrine and dopamine reuptake inhibitors (NDRI). CI, confidence interval; SD, standard definition; SNRI, selective serotonin and norepinephrine reuptake inhibitors.
Figure 9. Pooled effect on working memory for selective serotonin reuptake inhibitors (SSRI) versus norepinephrine and dopamine reuptake inhibitors (NDRI). CI, confidence interval; SD, standard definition; SNRI, selective serotonin and norepinephrine reuptake inhibitors.CC BY · PubMed Central
Figure 10. Pooled effect on psychomotor speed (Digit Symbol Sign Test [DSST]) for sertraline versus fluoxetine. CI, confidence interval; SD, standard definition.
Figure 10. Pooled effect on psychomotor speed (Digit Symbol Sign Test [DSST]) for sertraline versus fluoxetine. CI, confidence interval; SD, standard definition.CC BY · PubMed Central

Verification

Claims the paper makes

5 Valid · 2 Not valid · 3 Not checked · 36 Own results and interpretations

26 more claims

Create a free account to see all 46 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 9
  • Probably not a substantial claim. 5
  • Borderline: one of the tests for a substantial claim is unclear. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 32 references

Cited by

Items 201–300 of 317

Metadata

Authors
Rosenblat, J. D., Kakar, R., & McIntyre, R. S.
Affiliations
Western University (CA)
Corresponding author
McIntyre, Roger S
Venue
International Journal of Neuropsychopharmacology
Published
2015-07-25
Volume
19
Issue
2
Pages
pyv082
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W2212064423
Cited by
315
References
32
Citations by year
2026: 8 · 2025: 27 · 2024: 43 · 2023: 34 · 2022: 28 · 2021: 32 · 2020: 23 · 2019: 35 · 2018: 27 · 2017: 27 · 2016: 27 · 2015: 3
FWCI
3.52
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
major depressive disorder, antidepressants, cognitive impairment, psychomotor speed, delayed recall, executive function, cognitive control, vortioxetine, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants
MeSH terms
Antidepressive Agents, Cognition, Cognition Disorders, Major Depressive Disorder, Humans, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.